SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001213900-20-031744
Filing Date
2020-10-16
Accepted
2020-10-16 16:16:27
Documents
4
Group Members
ENRICO CAVAZZAFRANCESCA CAVAZZAMARTINA CAVAZZA PRETAPAOLO CAVAZZASILVIA CAVAZZA

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 24 TO SCHEDULE 13D ea128386-13da24esset_regen.htm SC 13D/A 153584
2 CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT, DATED OCTOBER 15, 2020, BETWEEN ea128386ex99-6_essetifin.htm EX-99.6 159831
3 FORM OF OCTOBER 2020 NOTE ea128386ex99-7_essetifin.htm EX-99.7 39571
4 FORM OF OCTOBER 2020 WARRANT ea128386ex99-8_essetifin.htm EX-99.8 71572
  Complete submission text file 0001213900-20-031744.txt   426302
Mailing Address 15245 SHADY GROVE ROAD SUITE 470 ROCKVILLE MD 20850
Business Address 15245 SHADY GROVE ROAD SUITE 470 ROCKVILLE MD 20850 301-208-9191
REGENERX BIOPHARMACEUTICALS INC (Subject) CIK: 0000707511 (see all company filings)

IRS No.: 521253406 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-37889 | Film No.: 201244217
SIC: 2834 Pharmaceutical Preparations

Mailing Address VIA SUDAFRICA 20 ROME L6 00144
Business Address
Essetifin SPA (Filed by) CIK: 0001092601 (see all company filings)

Fiscal Year End: 1231
Type: SC 13D/A